These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16757435)

  • 21. Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case report and review of literature.
    Tang Y; Wang Y; Hu L; Meng F; Xu D; Wan K; Huang L; Li C; Zhou J
    Int J Clin Exp Pathol; 2015; 8(11):15294-300. PubMed ID: 26823883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute promyelocytic leukaemia complicating multiple myeloma: evidence of different cell lineages.
    Dunkley S; Gibson J; Iland H; Li C; Joshua D
    Leuk Lymphoma; 1999 Nov; 35(5-6):623-6. PubMed ID: 10609802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
    Rock N; Mattiello V; Judas C; Huezo-Diaz P; Bourquin JP; Gumy-Pause F; Ansari M
    Pediatr Hematol Oncol; 2014 Mar; 31(2):143-8. PubMed ID: 24498972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
    Iland HJ; Wei A; Seymour JF
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
    Aribi A; Kantarjian HM; Estey EH; Koller CA; Thomas DA; Kornblau SM; Faderl SH; Laddie NM; Garcia-Manero G; Cortes JE
    Cancer; 2007 Apr; 109(7):1355-9. PubMed ID: 17326049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
    Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
    Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.
    de Botton S; Fawaz A; Chevret S; Dombret H; Thomas X; Sanz M; Guerci A; San Miguel J; de la Serna J; Stoppa AM; Reman O; Stamatoulas A; Fey M; Cahn JY; Sotto JJ; Bourhis JH; Parry A; Chomienne C; Degos L; Fenaux P
    J Clin Oncol; 2005 Jan; 23(1):120-6. PubMed ID: 15534358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
    Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
    Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
    Testa U; Lo-Coco F
    Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early relapse after non myeloablative allogeneic stem cell transplantation in a patient with acute promyelocytic leukemia in complete molecular remission.
    Tavernier E; Thomas X
    Indian J Cancer; 2003; 40(4):140-3. PubMed ID: 14716110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation.
    Perego RA; Marenco P; Bianchi C; Cairoli R; Urbano M; Nosari AM; Muti G; Morra E; Del Monte U
    Leukemia; 1996 Feb; 10(2):207-12. PubMed ID: 8637228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive value of RT-PCR PML-RARA transcript monitoring for extramedullary relapse of acute promyelocytic leukemia in the pleura, heart and pericardium after allogeneic SCT.
    Nasilowska-Adamska B; Majewski M; Seferynska I; Szczepinski A; Tomaszewska A; Prochorec-Sobieszek M; Guz K; Torbicki A; Warzocha K; Marianska B
    Ann Transplant; 2007; 12(3):33-8. PubMed ID: 18290568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
    Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
    Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
    Soignet SL; Maslak P; Wang ZG; Jhanwar S; Calleja E; Dardashti LJ; Corso D; DeBlasio A; Gabrilove J; Scheinberg DA; Pandolfi PP; Warrell RP
    N Engl J Med; 1998 Nov; 339(19):1341-8. PubMed ID: 9801394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cryptic insertion (15;17) in a case of acute promyelocytic leukemia detected by fluorescence in situ hybridization.
    Gutiérrez NC; García JL; Chillón C; Muntión S; González M; Hernández JM
    Haematologica; 1999 Jan; 84(1):88-90. PubMed ID: 10091399
    [No Abstract]   [Full Text] [Related]  

  • 37. A t(17;20)(q21;q12) masking a variant t(15;17)(q22;q21) in a patient with acute promyelocytic leukemia.
    García-Casado Z; Cervera J; Valencia A; Pajuelo JC; Mena-Duran AV; Barragán E; Bolufer P; Sanz MA
    Cancer Genet Cytogenet; 2006 Jul; 168(1):73-6. PubMed ID: 16772124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
    Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
    Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
    Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
    J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Favourable outcome in an APL patient with PLZF/RARalpha fusion gene: quantitative real-time RT-PCR confirms molecular response.
    Cassinat B; Guillemot I; Moluçon-Chabrot C; Zassadowski F; Fenaux P; Tournilhac O; Chomienne C
    Haematologica; 2006 Dec; 91(12 Suppl):ECR58. PubMed ID: 17194664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.